霍奇金淋巴瘤

Eichenauer DA, Aleman BM, André M, et al. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(supplement_4):iv19-29.全文  摘要

Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 Sep 20;28(27):4199-206. 摘要

Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010 Aug 12;363(7):640-52.全文  摘要

Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 Apr 23;372(17):1598-607.全文  摘要

Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009 Nov 10;27(32):5390-6. 摘要

Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 May 12;379(9828):1791-9. 摘要

Schmitz N, Pfistner B, Sextro M, et al; German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002 Jun 15;359(9323):2065-71. 摘要

Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. 摘要

1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19;127(20):2375-90.全文  摘要

2. Pileri SA, Ascani S, Leoncini L, et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol. 2002 Mar;55(3):162-76.全文  摘要

3. Kaseb H, Babiker HM. StatPearls: cancer, Hodgkin lymphoma. Treasure Island, FL: StatPearls Publishing; 2019.全文  摘要

4. Eichenauer DA, Aleman BM, André M, et al. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(supplement_4):iv19-29.全文  摘要

5. Cancer Research UK. Hodgkin lymphoma incidence statistics. 2019 [internet publication].全文

6. National Cancer Institute. SEER stat fact sheets: Hodgkin lymphoma. 2019 [internet publication].全文

7. Macfarlane GJ, Evstifeeva T, Boyle P, et al. International patterns in the occurrence of Hodgkin's disease in children and young adult males. Int J Cancer. 1995 Apr 10;61(2):165-9. 摘要

8. Cartwright RA, Watkins G. Epidemiology of Hodgkin's disease: a review. Hematol Oncol. 2004 Mar;22(1):11-26. 摘要

9. Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med. 2003 Oct 2;349(14):1324-32.全文  摘要

10. Kerzin-Storrar L, Faed MJ, MacGillivray JB, et al. Incidence of familial Hodgkin's disease. Br J Cancer. 1983 May;47(5):707-12. 摘要

11. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000 Feb 15;95(4):1443-50.全文  摘要

12. Lam KP, Kühn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997 Sep 19;90(6):1073-83.全文  摘要

13. Schweighoffer E, Tybulewicz VL. Signalling for B cell survival. Curr Opin Cell Biol. 2017 Nov 14;51:8-14.全文  摘要

14. Portis T, Ikeda M, Longnecker R. Epstein-Barr virus LMP2A: regulating cellular ubiquitination processes for maintenance of viral latency? Trends Immunol. 2004 Aug;25(8):422-6. 摘要

15. Kilger E, Kieser A, Baumann M, et al. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 1998 Mar 16;17(6):1700-9.全文  摘要

16. Weiss LM, Movahed LA, Warnke RA, et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med. 1989 Feb 23;320(8):502-6. 摘要

17. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer. 1997 Feb 7;70(4):375-82. 摘要

18. Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med. 1989 Mar 16;320(11):689-95. 摘要

19. Paltiel O, Schmit T, Adler B, et al. The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphoma: results and limitations of a registry-linked study. Cancer. 2000 May 15;88(10):2357-66. 摘要

20. Kharazmi E, Fallah M, Pukkala E, et al. Risk of familial classical Hodgkin lymphoma by relationship, histology, age, and sex: a joint study from five Nordic countries. Blood. 2015 Aug 26;126(17):1990-5.全文  摘要

21. Mack TM, Cozen W, Shibata DK, et al. Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med. 1995 Feb 16;332(7):413-8.全文  摘要

22. Grufferman S, Cole P, Smith PG, et al. Hodgkin's disease in siblings. N Engl J Med. 1977 Feb 3;296(5):248-50. 摘要

23. Clarke CA, Glaser SL, Keegan TH, et al. Neighborhood socioeconomic status and Hodgkin's lymphoma incidence in California. Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1441-7.全文  摘要

24. Westergaard T, Melbye M, Pedersen JB, et al. Birth order, sibship size and risk of Hodgkin's disease in children and young adults: a population-based study of 31 million person-years. Int J Cancer. 1997 Sep 17;72(6):977-81. 摘要

25. Oza AM, Tonks S, Lim J, et al. A clinical and epidemiological study of human leukocyte antigen-DPB alleles in Hodgkin's disease. Cancer Res. 1994 Oct 1;54(19):5101-5.全文  摘要

26. Diepstra A, van Imhoff GW, Karim-Kos HE, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol. 2007 Jul 20;25(21):3101-8. 摘要

27. Gutensohn NM. Social class and age at diagnosis of Hodgkin's disease: new epidemiologic evidence for the "two-disease hypothesis." Cancer Treat Rep. 1982 Apr;66(4):689-95. 摘要

28. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007 Feb 10;25(5):571-8.全文  摘要

29. Cheson BD, Pfistner B, Juweid ME, Get al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. 摘要

30. Tubiana M, Attié E, Flamant R, et al. Prognostic factors in 454 cases of Hodgkin's disease. Cancer Res. 1971 Nov;31(11):1801-10. 摘要

31. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005 Sep 1;104(5):1066-74.全文  摘要

32. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med. 2002 Mar;112(4):262-8. 摘要

33. Cheng G, Alavi A. Value of 18F-FDG PET versus iliac biopsy in the initial evaluation of bone marrow infiltration in the case of Hodgkin's disease: a meta-analysis. Nucl Med Commun. 2013 Jan;34(1):25-31. 摘要

34. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989 Nov;7(11):1630-6. 摘要

35. German Hodgkin Study Group. Disease stages and risk factors. 2019 [internet publication].全文

36. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol. 2004 Jan 1;22(1):62-8.全文  摘要

37. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005 Jul 20;23(21):4634-42.全文  摘要

38. Noordijk EM, Thomas J, Ferme C, et al. First results of the EORTC-GELa H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). 2005 ASCO Annual Meeting Proceedings. J Clin Oncol. 2005;23(16 suppl):6505.全文

39. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004 Dec 1;104(12):3483-9.全文  摘要

40. Blank O, von Tresckow B, Monsef I, et al. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2017 Apr 27;(4):CD007110.全文  摘要

41. Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 Sep 20;28(27):4199-206. 摘要

42. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010 Aug 12;363(7):640-52.全文  摘要

43. Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015 Apr 11;385(9976):1418-27. 摘要

44. Böll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5;127(18):2189-92.全文  摘要

45. Franklin J, Eichenauer DA, Becker I, et al. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis. Cochrane Database Syst Rev. 2017 Sep 13;(9):CD008814.全文  摘要

46. von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol. 2012 Mar 20;30(9):907-13.全文  摘要

47. Connors JM. The case for chemotherapy alone for limited-stage Hodgkin's lymphoma. Oncologist. 2012;17(8):1011-3.全文  摘要

48. Hill-Kayser CE, Plastaras JP, Tochner Z, et al. The case for combined-modality therapy for limited-stage Hodgkin's disease. Oncologist. 2012;17(8):1006-10.全文  摘要

49. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012 Feb 2;366(5):399-408.全文  摘要

50. Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014 Apr 20;32(12):1188-94.全文  摘要

51. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 Apr 23;372(17):1598-607.全文  摘要

52. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol. 2009 Nov 10;27(32):5390-6. 摘要

53. Federico M, Luminari S, Iannitto E, et al; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009 Feb 10;27(5):805-11. 摘要

54. Skoetz N, Will A, Monsef I, et al. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2017 May 25;(5):CD007941.全文  摘要

55. Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015 Sep 16;126(26):2798-804.全文  摘要

56. Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol. 2018 Sep 4;36(30):3015-22. 摘要

57. Connors JM, Jurczak W, Straus DJ, et al; ECHELON-1 Study Group. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2017 Dec 10;378(4):331-44.全文  摘要

58. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20;31(6):684-91. 摘要

59. Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419-29.全文  摘要

60. Aleman BM, Raemaekers JM, Tirelli U, et al; European Organization for Research and Treatment of Cancer Lymphoma Group. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2003 Jun 12;348(24):2396-406.全文  摘要

61. DeVita VT Jr. Hodgkin's disease - clinical trials and travails. N Engl J Med. 2003 Jun 12;348(24):2375-6. 摘要

62. Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med. 1994 Jun 1;120(11):903-12. 摘要

63. Prosnitz LR. Consolidation radiotherapy in the treatment of advanced Hodgkin's disease: is it dead? Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):605-8. 摘要

64. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 May 12;379(9828):1791-9. 摘要

65. Johnson PW, Sydes MR, Hancock BW, et al. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol. 2010 Jul 10;28(20):3352-9. 摘要

66. Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005 Oct;16(10):1683-7.全文  摘要

67. Eichenauer DA, Engert A. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):324-8.全文  摘要

68. Fanale MA, Cheah CY, Rich A, et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017 May 18;130(4):472-7.全文  摘要

69. Josting A, Nogová L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol. 2005 Mar 1;23(7):1522-9.全文  摘要

70. Constine LS, Yahalom J, Ng AK, et al. The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018 Jan 9;100(5):1100-18. 摘要

71. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993 Apr 24;341(8852):1051-4. 摘要

72. Schmitz N, Pfistner B, Sextro M, et al; German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002 Jun 15;359(9323):2065-71. 摘要

73. Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003 Dec;14(12):1762-7.全文  摘要

74. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001 Feb 1;97(3):616-23.全文  摘要

75. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica. 2007 Jan;92(1):35-41.全文  摘要

76. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012 Feb 16;119(7):1665-70.全文  摘要

77. Moskowitz CH, Nademanee A, Masszi T, et al; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 9;385(9980):1853-62. 摘要

78. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012 Jun 20;30(18):2183-9.全文  摘要

79. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015 Jan 22;372(4):311-9.全文  摘要

80. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1283-94.全文  摘要

81. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016 Nov 1;34(31):3733-9. 摘要

82. Anderlini P, Champlin RE. Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand? Biol Blood Marrow Transplant. 2006 Jun;12(6):599-602. 摘要

83. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. 摘要

84. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21;365(3):203-12.全文  摘要

85. Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016 Apr 10;34(11):1175-81.全文  摘要

86. Carde P, Karrasch M, Fortpied C, et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in stage III to IV, International Prognostic Score ≥ 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup Trial. J Clin Oncol. 2016 Jun 10;34(17):2028-36.全文  摘要

87. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006 Jul 1;24(19):3128-35.全文  摘要

88. Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol. 2001 Nov 15;19(22):4238-44. 摘要

89. Specht L, Gray RG, Clarke MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol. 1998 Mar;16(3):830-43. 摘要

90. Nachman JB, Sposto R, Herzog P, et al; Children's Cancer Group. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002 Sep 15;20(18):3765-71. 摘要

91. Herbst C, Rehan FA, Brillant C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica. 2010 Mar;95(3):494-500.全文  摘要

92. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003 Oct 1;21(19):3601-8. 摘要

93. Zittoun R, Audebert A, Hoerni B, et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol. 1985 Feb;3(2):207-14. 摘要

94. Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004 Jul 15;22(14):2835-41.全文  摘要

95. Bartlett NL, Rosenberg SA, Hoppe RT, et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol. 1995 May;13(5):1080-8. 摘要

96. Adams H, Obermann EC, Dirnhofer S, et al. Targetable molecular pathways in classical Hodgkin's lymphoma. Expert Opin Investig Drugs. 2011 Feb;20(2):141-51. 摘要

97. Sureda A, Younes A, Ben-Yehuda D, et al. Final analysis: phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant. Abstract 419. Paper presented at: 52nd ASH Annual Meeting and Exposition. 2010. Orlando, FL. Blood. 2010 Nov 19;116(21):419.全文

98. Younes A, Hernandez F, Bociek RG, et al. The HDAC inhibitor entinostat (SNDX-275) induces clinical responses in patients with relapsed and refractory Hodgkin's lymphoma: results of ENGAGE-501 multicenter phase 2 study. Abstract 2715. Paper presented at: 53rd ASH Annual Meeting and Exposition. 2011. San Diego, CA. Blood. 2011 Nov 18;118(21):2715.全文

99. Younes A, Bociek RG, Kuruvilla J, et al. Mocetinostat (MGCD0103), an isotype-selective histone deacetylase (HDAC) inhibitor, produces clinical responses in relapsed/refractory Hodgkin lymphoma (HL): update from a phase II clinical study. Abstract 1763. Paper presented at: 52nd ASH Annual Meeting and Exposition. 2010. Orlando, FL. Blood. 2010 Nov 19;116(21):1763.全文

100. Johnston PB, Pinter-Brown L, Rogerio J, et al. Open-label, single-arm, phase II study of everolimus in patients with relapsed/refractory classical Hodgkin lymphoma. Abstract 2717. Paper presented at: 53rd ASH Annual Meeting and Exposition. 2011. San Diego, CA. Blood. 2011 Nov 18;118(21):2717.全文

101. Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011 Nov 10;118(19):5119-25.全文  摘要

102. Moskowitz A, Hamlin P, Gerecitano J, et al. Updated results of a phase II trial of bendamustine in relapsed and refractory Hodgkin lymphoma. Abstract 288. Paper presented at: 11th International Conference on Malignant Lymphoma. 2011. Lugano (Switzerland). Ann Oncol. 2011 Jun;22(suppl 4):iv180-1.全文

103. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002 Apr 15;20(8):2101-8. 摘要

104. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003 Jun 12;348(24):2386-95. [Erratum in: N Engl J Med. 2005 Aug 18;353(7):744.]全文  摘要

105. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84. 摘要

106. Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005 Dec 20;23(36):9198-207.全文  摘要

107. Hasenclever D, Diehl V, Armitage JO, et al; International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score for advanced Hodgkin's disease. N Engl J Med. 1998 Nov 19;339(21):1506-14.全文  摘要

108. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002 Feb 1;20(3):630-7. 摘要

109. Delwail V, Jais JP, Colonna P, et al. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br J Haematol. 2002 Jul;118(1):189-94. 摘要

110. Koontz BF, Kirkpatrick JP, Clough RW, et al. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. J Clin Oncol. 2006 Feb 1;24(4):605-11.全文  摘要

111. De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009 Sep 10;27(26):4239-46. 摘要

112. Stewart JR, Fajardo LF. Dose response in human and experimental radiation-induced heart disease. Application of the nominal standard dose (NSD) concept. Radiology. 1971 May;99(2):403-8. 摘要

113. Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003 Aug 20;42(4):743-9. 摘要

114. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003 Dec 3;290(21):2831-7.全文  摘要

115. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993 Oct 27;270(16):1949-55. 摘要

116. Aviles A, Neri N, Nambo JM, et al. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma. 2005 Jul;46(7):1023-8. 摘要

117. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005 Oct 20;23(30):7614-20.全文  摘要

118. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med. 1991 Aug 29;325(9):599-605. 摘要

119. Anderson RA, Remedios R, Kirkwood AA, et al. Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. Lancet Oncol. 2018 Sep 13;19(10):1328-37.全文  摘要

120. Schmidt KT, Andersen CY; ISFP Practice Committee. Recommendations for fertility preservation in patients with lymphomas. J Assist Reprod Genet. 2012 Jun;29(6):473-7. 摘要

121. Dryver ET, Jernstrom H, Tompkins K, et al. Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. Br J Cancer. 2003 Aug 4;89(3):482-6. 摘要

122. Radford JA, Eardley A, Woodman C, et al. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ. 1997 Feb 1;314(7077):343-6. 摘要

123. Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol. 1997 Mar;15(3):1123-30. 摘要